Omada Health CEO Sean Duffy Sells Shares

On June 24, 2026, Sean Duffy, the Chief Executive Officer of Omada Health, Inc. (NasdaqGS: OMDA), sold 2,800 shares of the company. The shares were sold at an average price of $19.01 each, amounting to a total transaction value of $53,228. This sale was planned under a Rule 10b5-1 trading plan.

Insider Buying and Selling at Omada Health, Inc.

Sean Duffy, Omada Health's CEO, has been active in recent insider transactions. On June 26, 2026, he sold an additional 14,158 shares at an average price of $20.00. Other executives, including CFO Steven Cook and CAO Craig Gracey, have also sold shares in planned transactions. These sales are part of scheduled trading plans and do not necessarily indicate negative sentiment.

Other Institutional Activity in Omada Health

Several institutional investors have adjusted their positions in Omada Health. Divisadero Street Capital Management, LP significantly increased its holdings by 5,418,118 shares, bringing its total to 5,887,715 shares valued at approximately $74.0 million. FMR LLC, however, reduced its stake by 1,890,124 shares, now holding 3,288,380 shares worth about $41.3 million. American Century Companies Inc opened a new position with 2,456,309 shares valued at approximately $30.9 million.

Omada Health, Inc. Stock Down 11.8%

Shares of Omada Health traded near $20.89 on Saturday. The company has a market capitalization of roughly $1.12 billion and a forward P/E ratio of 39.67. Omada Health's stock has seen a 52-week low of $10.28 and a high of $26.92. The stock's 50-day moving average is $16.29, and its 200-day moving average is $17.15. The company maintains a solid current ratio of 3.92 and a quick ratio of 3.69.

Recent Earnings

Omada Health reported revenue of $283.3 million, reflecting a growth rate of 42%. Despite this, the company posted a net margin of -2.22% and a return on equity of -4.30%. The next earnings report is expected on May 7, 2026.

Analysts Set New Price Targets

On June 22, 2026, Morgan Stanley reiterated its buy rating on Omada Health with a price target of $30. Other analysts, including Barclays and Citizens, have also maintained buy ratings with targets ranging from $18 to $23. The average target price among analysts is approximately $22.92, based on 12 opinions.

About Omada Health

Omada Health, Inc., headquartered in South San Francisco, California, offers virtual care programs in the United States. The company provides services for prediabetes, diabetes, hypertension, musculoskeletal conditions, weight management, and behavioral health. These programs are available to employers, health plans, and pharmacy benefits managers through direct sales and partnerships. Omada Health was founded in 2011 and employs about 943 people.

Bottom Line

Sean Duffy's recent planned sale of Omada Health shares is part of a scheduled trading plan, and such insider transactions are common for executives. Omada Health's stock remains under the watch of institutional investors and analysts, with recent activity indicating varied sentiment. As always, 13F and insider filings offer a backward-looking view and may not reflect current positions.